Literature DB >> 18283711

Extranodal NK/T-cell lymphoma: diagnosis and treatment cues.

Ritsuro Suzuki1, Kengo Takeuchi, Koichi Ohshima, Shigeo Nakamura.   

Abstract

Extranodal NK/T-cell lymphoma, nasal type (ENKL) is mostly endemic to East Asia. It predominantly occurs in the nasal or paranasal areas and less frequently in the skin. Most of the tumours show NK-cell, but rarely T-cell, phenotypes. The Epstein-Barr virus (EBV) genome can be usually detected in lymphoma cells. Geographic localization of ENKL matches the endemic distribution of EBV, suggesting that EBV plays an important role in lymphomagenesis. Originally, NK-cell and T-cell types were believed to present the same clinicopathologic characteristics, but recent data suggest more aggressive characteristics for the NK-cell phenotype. Although ENKL is sensitive to radiotherapy, it shows a poorer response to chemotherapeutic agents than other lymphomas due to expression of p-glycoprotein. Therefore, new therapeutic approaches must be considered. Several new clinical trials are now being conducted in East Asia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18283711     DOI: 10.1002/hon.847

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  48 in total

1.  Extranodal natural killer/T cell lymphoma, nasal type presenting as a palatal perforation and naso-oral fistula.

Authors:  Vijaya Raj Bhatt; Bibek Koirala; Terenig Terjanian
Journal:  BMJ Case Rep       Date:  2011-03-01

2.  Clinicopathologic conference: case 2.

Authors:  Shabnum Meer; Willie F P van Heerden
Journal:  Head Neck Pathol       Date:  2008-09-10

Review 3.  Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.

Authors:  Bradley M Haverkos; Zenggang Pan; Alejandro A Gru; Aharon G Freud; Rachel Rabinovitch; Meng Xu-Welliver; Brad Otto; Carlos Barrionuevo; Robert A Baiocchi; Rosemary Rochford; Pierluigi Porcu
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

4.  L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma.

Authors:  Shanshan Bu; Fangfang Yuan; Xudong Wei; Qingsong Yin; Yufu Li; Ruihua Mi; Haiping Yang; Hongyi Li; Shoubei Ge; Yanyan Liu; Yongping Song
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

5.  Recurrent Extranodal NK/T-Cell Lymphoma Presenting as a Perforating Palatal Ulcer and Oro-Nasal Fistula.

Authors:  Kang Gyun Park; Eun Sang Dhong; Sik Namgoong; Jung Kyu Han; Seung Kyu Han; Woo Kyung Kim
Journal:  Arch Craniofac Surg       Date:  2016-09-23

Review 6.  Natural killer-cell neoplasms.

Authors:  John P Greer; Claudio A Mosse
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

7.  The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0.

Authors:  Ritsuro Suzuki; Shigeki Ohtake; Jin Takeuchi; Masami Nagai; Yoshihisa Kodera; Motohiro Hamaguchi; Shuichi Miyawaki; Takahiro Karasuno; Shigetaka Shimodaira; Ryuzo Ohno; Shigeo Nakamura; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-01-29       Impact factor: 2.490

8.  JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function.

Authors:  Theodoros Karantanos; Vassiliki A Boussiotis
Journal:  Transl Cancer Res       Date:  2016-11       Impact factor: 1.241

9.  Extranodal NK/T cell lymphoma, nasal type, of the small intestine diagnosed by double-balloon endoscopy.

Authors:  Shihoko Wakabayashi; Ayako Arai; Gaku Oshikawa; Akihiro Araki; Mamoru Watanabe; Naoyuki Uchida; Shuichi Taniguchi; Osamu Miura
Journal:  Int J Hematol       Date:  2009-11-20       Impact factor: 2.490

Review 10.  Extranodal NK/T-cell lymphoma nasal type: efficacy of pegaspargase. Report of two patients from the United Sates and review of literature.

Authors:  Vincent Edgar Reyes; Tahseen Al-Saleem; Valentin G Robu; Mitchell R Smith
Journal:  Leuk Res       Date:  2009-09-27       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.